Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
British Journal of Haematology|January 6, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemiaSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Nature Communications|December 31, 2024
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemiaDorian Forte, Roberto Maria Pellegrino, Paolo Falvo, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Cancers|December 11, 2019
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid LeukemiaAntonella Padella, Giorgia Simonetti, Giulia Paciello, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Leukemia|February 24, 2018
Chromothripsis in acute myeloid leukemia: biological features and impact on survivalMaria Chiara Fontana, Giovanni Marconi, Jelena D Milosevic Feenstra, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
British Journal of Haematology|January 6, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemiaSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Nature Communications|December 31, 2024
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemiaDorian Forte, Roberto Maria Pellegrino, Paolo Falvo, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Cancers|December 11, 2019
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid LeukemiaAntonella Padella, Giorgia Simonetti, Giulia Paciello, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Leukemia|February 24, 2018
Chromothripsis in acute myeloid leukemia: biological features and impact on survivalMaria Chiara Fontana, Giovanni Marconi, Jelena D Milosevic Feenstra, et al.
Pageof 17